摘要
克唑替尼是目前治疗非小细胞肺癌的有效药物,研究发现其能抑制肿瘤细胞增殖、诱导肿瘤细胞凋亡、抑制肿瘤的侵袭与转移。克唑替尼抗肿瘤作用涉及间变淋巴瘤激酶、HGF/c-MET信号通路、原癌基因蛋白酪氨酸激酶、Bim凋亡基因、雷帕霉素靶蛋白、低氧诱导因子1等,近年临床治疗中发现克唑替尼出现耐药情况,未来对其抗肿瘤作用及耐药机制仍需进一步深入研究。
Crizotinib is effective to treat non small cell lung cancer, the study has found that it can inhibit the proliferation of tumor cells, induce tumor cells apoptosis and inhibit tumor cells invade and transfer. Crizotinib anti-tumor effect involving the anaplastic lymphoma kinase, HGF/c-MET signaling pathway, c-ros oncogene 1 receptor tyrosine kinase, Bim gene, mammalian target of rapamycin, hypoxia induced factor-1, the clinical treatment has found that crizotinib appear resistance in recent years, so its anti-tumor and drug resistance mechanism still need further study in the furture.
出处
《中国现代医生》
2015年第14期156-160,共5页
China Modern Doctor
